bictegravir/emtricitabine/tenofovir vs estradiol
Side-by-side comparison of bictegravir/emtricitabine/tenofovir and estradiol. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
minor Known Drug Interaction
7.6 Drugs without Clinically Significant Interactions with BIKTARVY Based on drug interaction studies conducted with BIKTARVY or the components of BIKTARVY, no clinically significant drug interactions have been observed when BIKTARVY is combined with the following drugs: ethinyl estradiol, ledipasvir/sofosbuvir, midazolam, norgestimate, sertraline, sofosbuvir, sofosbuvir/velpatasvir, and sofosbuvir/velpatasvir/voxilaprevir.
Recommendation: No adjustments to your treatment are needed when using these two drugs together.
Biktarvy
Estrace, Vivelle-Dot
Biktarvy is a complete HIV-1 treatment for adults and children who weigh at least 31 pounds. It combines three medicines into one tablet to help control the virus.
Iclevia is a birth control pill. It contains two hormones, a progestin and an estrogen, that work together to prevent pregnancy.
Biktarvy treats Human Immunodeficiency Virus type 1 (HIV-1) in adults and children weighing at least 31 pounds. It can be used if you have never taken HIV medicine before. It can also replace your current HIV medicine if your virus is under control and you have no resistance to Biktarvy's components.
Iclevia is used by women who can get pregnant to prevent pregnancy. It contains two types of hormones. These hormones stop you from releasing an egg and also change the lining of your uterus, which prevents pregnancy.
Biktarvy contains three drugs that each block HIV in different ways. Bictegravir stops HIV from inserting its DNA into your cells. Emtricitabine and tenofovir alafenamide interfere with an enzyme HIV needs to make copies of itself.
Iclevia contains two hormones: levonorgestrel (a progestin) and ethinyl estradiol (an estrogen). These hormones prevent pregnancy by stopping ovulation (the release of an egg from the ovary). They also change the lining of the uterus to prevent a fertilized egg from implanting.
- • Diarrhea
- • Nausea
- • Headache
- • Headache
- • Heavy menstrual bleeding
- • Nausea
- • Painful periods
- • Acne
No adverse event reports.
- The product did not stick properly 5,172
- Headache 5,035
- Nausea 4,752
- Tiredness 4,511
- Pain 3,478
If you have both HIV and hepatitis B, stopping Biktarvy can cause your hepatitis B to suddenly get worse. Your doctor will need to monitor your liver closely for several months after you stop taking Biktarvy. You may need to take medicine for hepatitis B.
Cigarette smoking increases your risk of serious heart problems from birth control pills. This risk is higher if you are over 35 and smoke more cigarettes. You should not take Iclevia if you are over 35 and smoke.
There is a pregnancy registry to track outcomes in women who take Biktarvy during pregnancy. Talk to your doctor about the risks and benefits of taking Biktarvy if you are pregnant or planning to become pregnant. There is not enough data to assess the risk of major birth defects.
Do not use Iclevia if you are pregnant. If you become pregnant while taking Iclevia, stop taking it right away. Iclevia can reduce milk production, so you may want to use a different birth control method while breastfeeding.
Also Compare, Nearby Drugs
Compare bictegravir/emtricitabine/tenofovir with
How to Read This bictegravir/emtricitabine/tenofovir vs estradiol Comparison
bictegravir/emtricitabine/tenofovir is classified in the Integrase Inhibitor / NRTI Combination drug class, while estradiol sits within the Estrogen Hormone class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, bictegravir/emtricitabine/tenofovir has 0 submissions while estradiol has 22,948. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. These two drugs have a known minor interaction flagged in FDA labeling, attributed to clinical studies show that these drugs do not interfere with each other when taken at the same time.. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot substitute for clinical judgment. Effectiveness, tolerability, drug-drug interactions with your other medications, kidney and liver function, pregnancy status, insurance formulary, and price all feed into a decision that only a licensed prescriber can make responsibly. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This page is for educational purposes only, is not medical advice, and should not be used to self-switch between bictegravir/emtricitabine/tenofovir and estradiol - always consult your physician or pharmacist first.
Important: This comparison is for informational purposes only. Drug effects vary between individuals. Always consult your doctor or pharmacist for personalized medical advice.